Unraveling bioenergetic heterogeneity of malignant tumors: prospects for development of targeted therapies.

被引：0
|
作者：
Tarasova, G. R. [1 ]
Gomzikova, M. O. [1 ]
Rizvanov, A. [1 ]
Cherepnev, G. V. [1 ]
Kalacheva, N. V. [1 ]
机构：
[1] Kazan Fed Univ, Inst Fundamental Med & Biol, Kazan, Russia
来源：
MOLECULAR BIOLOGY OF THE CELL | 2018年 / 29卷 / 26期
关键词：
D O I：
暂无
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
P2352
引用
收藏
页数：2
相关论文
共 28 条
  • [21] Development of targeted therapies for triple-negative breast cancer: can we harness tumor heterogeneity to improve patient outcomes?
    Diamond, Jennifer R.
    Elias, Anthony D.
    BREAST CANCER MANAGEMENT, 2013, 2 (03) : 175 - 178
  • [22] Development of targeted cytokine/suicide gene therapy for naturally occurring canine malignant tumors: A model for human cancer therapy?
    Argyle, DJ
    Nasir, L
    McGillivery, C
    Nicolson, L
    Onions, DE
    CANCER GENE THERAPY, 1998, 5 (06) : S17 - S17
  • [23] A national registry for the off-label use of targeted therapies in patients (pts) with malignant mesanchymal tumors: A retrospective study from the GSF-GETO
    Bay, J.
    Le Cesne, A.
    Cioffi, A.
    Penel, N.
    Duffaud, F.
    Cupissol, D.
    Piperno-Neumann, S.
    Cropet, C.
    Bouclier, L.
    Ray-Coquard, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] Re-biopsy in advanced non-small cell lung cancer patients after the development of 3rd generation EGFR-TKI and new targeted therapies.
    Nosaki, Kaname
    Inamasu, Eiko
    Shimamatsu, Shin-ichiro
    Yoshida, Tsukihisa
    Toyokawa, Goji
    Hirai, Fumihiko
    Yamaguchi, Masafumi
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Gastrointestinal stromal tumors - A model for understanding solid tumor biology and development of targeted therapies, or just another low-hanging fruit?
    Vilain, Ricardo E.
    Ackland, Stephen P.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2008, 4 (04) : 185 - 187
  • [26] Safety, pharmacokinetics (PK), pharmacodynamics (Pd), and antitumor activity in a phase 1b study evaluating anti-ErbB3 antibody KTN3379 in adults with advanced tumors alone and with targeted therapies.
    Falchook, Gerald Steven
    Bauer, Todd Michael
    LoRusso, Patricia
    McLaughlin, Joseph Francis
    LaVallee, Theresa
    Peck, Ronald Alan
    Eder, Joseph Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Hybrid-integrated devices for mimicking malignant brain tumors ("tumor-on-a-chip") for in vitro development of targeted drug delivery and personalized therapy approaches
    Zimina, Tatiana M.
    Sitkov, Nikita O.
    Gareev, Kamil G.
    Mikhailova, Natalia V.
    Combs, Stephanie E.
    Shevtsov, Maxim A.
    FRONTIERS IN MEDICINE, 2024, 11
  • [28] Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors
    Li, Fanfan
    Zhao, Shuping
    Wei, Cheng
    Hu, Yaodi
    Xu, Tianlong
    Xin, Xueyi
    Zhu, Tingwei
    Shang, Liting
    Ke, Shanwen
    Zhou, Jiang
    Xu, Xiaojun
    Gao, Yue
    Zhao, Ai
    Gao, Jimin
    FRONTIERS IN IMMUNOLOGY, 2022, 13
123